Skip to main content

Advertisement

SpringerLink
Log in

Endocrine manifestations of systemic mastocytosis in bone

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Systemic Mastocytosis (SM) is characterized by accumulation of clonal, neoplastic proliferations of abnormal mast cells (MC) in one or more organ system other than skin. Presence of these multifocal clusters of abnormal mast cells is an essential feature of SM. Frequently associated with D816V (KIT) mutation, the presence of this mutation and elevated serum tryptase are minor criteria for diagnosis. SM manifestations depend on the degree of mast cell proliferation, activation and degranulation. SM has a variable prognosis and presentation, from indolent to “smoldering” to life-threatening disease. Bone manifestations of SM include: osteopenia with or without lytic lesions, osteoporosis with or without atraumatic fracture, osteosclerosis with increased bone density, and isolated lytic lesions. Male sex, older age, higher bone resorption markers, lower DKK1 level, lower BMD, absence of urticaria pigmentosa, and alcohol intake are all associated with increased risk of fracture. Treatment of SM is generally palliative. Most therapy is symptom-directed; and, infrequently, chemotherapy for refractory symptoms is indicated. Anti-histamines may alleviate direct bone effects of histamine. Bisphosphonates, including alendronate, clodronate, pamidronate and zoledronic acid are recommended as a first line treatment of SM and osteoporosis. Interferon α may act synergistically with bisphosphonates. As elevation of RANKL and OPG is reported in SM, denosumab could be an effective therapy for bone manifestations of SM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 2014;34(2):283–95.

    Article  Google Scholar 

  2. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80(9):2237–45.

    CAS  PubMed  Google Scholar 

  3. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009;113(23):5727–36.

    Article  CAS  PubMed  Google Scholar 

  4. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–32.

    Article  CAS  PubMed  Google Scholar 

  5. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(19):1885–6.

    PubMed  Google Scholar 

  6. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat Immunol. 2011;12(11):1035–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol. 2001;116(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  8. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD, Carter MC. Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53(4):629–34.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Berezowska S, Flaig MJ, Ruëff F, Walz C, Haferlach T, Krokowski M, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014;27(1):19–29.

    Article  CAS  PubMed  Google Scholar 

  10. Lidor C, Frisch B, Gazit D, Gepstein R, Hallel T, Mekori YA. Osteoporosis as the sole presentation of bone marrow mastocytosis. J Bone Miner Res. 1990;5(8):871–6.

    Article  CAS  PubMed  Google Scholar 

  11. Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, et al. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int. 2015;96(5):410–6.

    Article  CAS  PubMed  Google Scholar 

  12. Alpay Kanıtez N, Erer B, Doğan Ö, Büyükbabani N, Baykal C, Sindel D, et al. Osteoporosis and osteopathy markers in patients with mastocytosis. Turk J Haematol. 2015;32(1):43–50.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, et al. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol. 2014;134(6):1413–21.

    Article  PubMed  Google Scholar 

  14. Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int. 2013;24(8):2325–34.

    Article  CAS  PubMed  Google Scholar 

  15. Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, et al. Bone complications of mastocytosis: A link between clinical and biological characteristics. Am J Med. 2013;126(1):75. e1-7.

    Article  PubMed  Google Scholar 

  16. Van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431–8.

    Article  PubMed  Google Scholar 

  17. Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med. 2011;124(8):776–8.

    Article  CAS  PubMed  Google Scholar 

  18. Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone. 2011;49(4):880–5.

    Article  PubMed  Google Scholar 

  19. Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis. 2010;69(10):1838–41.

    Article  CAS  PubMed  Google Scholar 

  20. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514–21.

    Article  PubMed  Google Scholar 

  21. Rossini M, Zanotti R, Viapiana O, Tripi G, Idolazzi L, Biondan M, et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med. 2014;127(11):1127. e1-4.

    Article  PubMed  Google Scholar 

  22. Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, Förster A, et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol. 2013;132(5):1234–7.

    Article  CAS  PubMed  Google Scholar 

  23. Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol. 2006;139(3):265–70.

    Article  CAS  PubMed  Google Scholar 

  24. Johansson C, Roupe G, Lindstedt G, Mellström D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996;25(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  25. Abramowitz JD. Weinerman SA Osteoporosis as the sole manifestation of systemic mastocytosis in a young man. Endocr Pract. 2012;18(6):e158–161.

    Article  PubMed  Google Scholar 

  26. Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am. 2014;34(2):383–96.

    Article  Google Scholar 

  27. Benucci M, Bettazzi C, Bracci S, Fabiani P, Monsacchi L, Cappelletti C, et al. Systemic mastocytosis with skeletal involvement: A case report and review of the literature. Clin Cases Miner Bone Metab. 2009;6(1):66–70.

    PubMed  PubMed Central  Google Scholar 

  28. Rossini M, Viapiana O, Adami S, Idolazzi L, Zanotti R, Gatti D. Rapid skeletal turnover in radiographic mimic of osteopetrosis might be secondary to systemic mastocytosis [corrected]. J Bone Miner Res. 2015;30(5):945.

    Article  PubMed  Google Scholar 

  29. Semënov MV, Tamai K, Brott BK, Kühl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol. 2001;11(12):951–61.

    Article  PubMed  Google Scholar 

  30. Fitzpatrick LA, Buzas E, Gagne TJ, Nagy A, Horvath C, Ferencz V, et al. Targeted deletion of histidine decarbosylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci USA. 2003;100(10):6027–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Graves 3rd L, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res. 1990;5(11):1113–9.

    Article  PubMed  Google Scholar 

  32. Pochampally RR, Ylostalo J, Penfornis P, Matz RR, Smith JR, Prockop DJ. Histamine receptor H1 and dermatopontin: New downstream targets of the vitamin D receptor. J Bone Miner Res. 2007;22(9):1338–49.

    Article  CAS  PubMed  Google Scholar 

  33. Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum. 2006;36(1):32–6.

    Article  CAS  PubMed  Google Scholar 

  34. Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, Møller MB, Bindslev-Jensen C, et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol. 2013;132(3):723–8.

    Article  CAS  PubMed  Google Scholar 

  35. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol. 1996;72(1):41–3.

    Article  CAS  PubMed  Google Scholar 

  36. Pardanani A. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015;90(3):250–62.

    Article  CAS  PubMed  Google Scholar 

  37. Lim AY, Ostor AJ, Love S, Crisp AJ. Systemic mastocytosis: A rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis. 2005;64(6):965–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Laroche M, Bret J, Brouchet A, Mazières B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol. 2007;26(2):242–3.

    Article  CAS  PubMed  Google Scholar 

  39. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol. 1997;36(3):393–6.

    Article  CAS  PubMed  Google Scholar 

  40. Cundy T, Beneton MN, Darby AJ, Marshall WJ, Kanis JA. Osteopenia in systemic mastocytosis: Natural history and responses to treatment with inhibitors of bone resorption. Bone. 1987;8(3):149–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, and ObGyn, NYU School of Medicine, 650 First Avenue, 7th Floor, New York, NY, 10016, USA

    Loren Wissner Greene

  2. Department of Medicine, Division of Endocrinology, NYU School of Medicine, 462 1st Avenue, New York, NY, 10016, USA

    Kamyar Asadipooya

  3. Department of Medicine, Division of Endocrinology, NYU School of Medicine, c/o Ira Goldberg, MD 522 First Avenue, Smilow 901, New York, NY, 10016, USA

    Patricia Freitas Corradi

  4. Department of Medicine, Division of Rheumatology, Immunology and Allergy, Mastocytosis Center, Brigham and Women’s Hospital, Harvard Medical School, One Jimmy Fund Way, Room 616D, Boston, MA, 02115, USA

    Cem Akin

Authors
  1. Loren Wissner Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamyar Asadipooya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia Freitas Corradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cem Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Loren Wissner Greene.

Ethics declarations

Conflict of interest statement

Loren Wissner Greene declares that there is no Conflict of Interest.

Kamyar Asadipooya declares that there is no Conflict of Interest.

Patricia Freitas Corradi declares that there is no Conflict of Interest.

Cem Akin declares that there is no Conflict of Interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greene, L.W., Asadipooya, K., Corradi, P.F. et al. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord 17, 419–431 (2016). https://doi.org/10.1007/s11154-016-9362-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-016-9362-3

Keywords

Search

Navigation